Matritech Announces Promising Results for Cancer Detection Product

Strategic Insights -

Researchers at Matritech have made a significant breakthrough in the development of a cancer detection product, NMP179, which has shown high accuracy in detecting pre-cancerous cervical abnormalities. The product uses nuclear matrix protein (NMP) technology to identify cancer markers in body fluids, offering a more reliable and early diagnosis of cervical cancer. This innovation has the potential to overcome the limitations of traditional Pap smear tests and provide accurate detection of cancer in its early stages.

Key Takeaways:

  • The preclinical study conducted by Matritech in collaboration with Brigham and Women's Hospital and Women and Infants Hospital detected 100% of precancerous high-grade or advanced cervical dysplasia and 76.7% of precancerous low-grade or early-stage cervical dysplasia using the NMP179 monoclonal antibody.
  • NMP179 has shown high sensitivity in detecting pre-cancerous cervical abnormalities, indicating its potential as a valuable diagnostic tool for physicians.
  • The development of NMP179 is part of Matritech's proprietary NMP technology, which was discovered at the Massachusetts Institute of Technology (MIT) and licensed exclusively to the company.
  • The product is designed to provide an accurate and early detection of patients who may not yet exhibit visible abnormalities in cervical tissue samples.
  • The American Cancer Society estimates that 13,700 new cases of cervical cancer will be diagnosed in the United States during 1998.

Statistics:

  • 100% of precancerous high-grade or advanced cervical dysplasia detected by NMP179
  • 76.7% of precancerous low-grade or early-stage cervical dysplasia detected by NMP179
  • 13,700 new cases of cervical cancer estimated to be diagnosed in the United States during 1998
  • 4,900 individuals estimated to die from cervical cancer in the United States in 1998

Sources:

  • PRNewswire "Matritech Announces Preclinical Evaluation of NMP179" (May 20, 1998)
  • American Cancer Society "Cervical Cancer Facts" (no date specified)
  • Food and Drug Administration (FDA) "NMP22(R) Test Kit Approval" (no date specified)
  • Matritech, Inc. "Company Overview" (no date specified)